A Phase 2 interventional study of IVIEW-1201 and Ofloxacin Eye Drops in Acute Bacterial Conjunctivitis, sponsored by IVIEW Therapeutics Inc.. Completed at 1 site in China. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by IVIEW Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis
40 studies on the registry are indexed under Conjunctivitis, Bacterial; 2 are open to participants now.
This study's enrollment of 129 is below the median of 261 across 36 interventional studies indexed under Conjunctivitis, Bacterial.
Browse Conjunctivitis, Bacterial studies →IVIEW Therapeutics Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A diagnosis of acute bacterial conjunctivitis based on clinical observations:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IVIEW-1201
Drug: Ofloxacin Eye Drops
Four times per day for day 1-2 and three times per day for day 3-7
Four times per day for day 1-2 and three times per day for day 3-7
Clinical Cure Rate
The proportion of subjects with a score of 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for bulbar conjunctival congestion and 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for conjunctival secretion/exudation at Visit 4 (Day 8±1), Visit 5 (Day 14±1).
Time frame: Take the visit 4 (Day 8±1) data, unless the subject was not cured and did not continue the treatment after visit 4 (Day 8±1) , in which case, visit 5 (Day 14±1) data would be used instead of Visit 4 data (Day 8±1).
Clearance Rate
Bacterial clearance is defined as positive bacterial culture at baseline and negative bacterial culture at the last visit.
Time frame: Day 3, Day 6, Day 8±1, Day 14±1
| Milestone | IVIEW-1201 | Ofloxacin Eye Drops |
|---|---|---|
| Started | 65 | 64 |
| Completed | 63 | 62 |
| Not completed | 2 | 2 |
The proportion of subjects with a score of 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for bulbar conjunctival congestion and 0 (0=Absent, 1=Mild, 2=Moderate, 3=Severe.) for conjunctival secretion/exudation at Visit 4 (Day 8±1), Visit 5 (Day 14±1).
| Participants | IVIEW-1201 | Ofloxacin Eye Drops |
|---|---|---|
| Clinically Cured | 37 | 31 |
| Not Clinically Cured | 27 | 33 |
Bacterial clearance is defined as positive bacterial culture at baseline and negative bacterial culture at the last visit.
| Participants | IVIEW-1201 | Ofloxacin Eye Drops |
|---|---|---|
| Day 3 — Cleared | 23 | 33 |
| Day 3 — Not Cleared | 19 | 9 |
| Day 6 — Cleared | 21 | 33 |
| Day 6 — Not Cleared | 21 | 9 |
| Day 8±1 — Cleared | 25 | 37 |
| Day 8±1 — Not Cleared | 17 | 5 |
| Day 14±1 — Cleared | 30 | 34 |
| Day 14±1 — Not Cleared | 12 | 8 |
Collected over Through participants completion of the study, an average of 2 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IVIEW-1201 | 0/64 (0%) | 1/64 (1.6%) | 11/64 (17.2%) |
| Ofloxacin Eye Drops | 0/64 (0%) | 0/64 (0%) | 0/64 (0%) |
| Event | IVIEW-1201 | Ofloxacin Eye Drops |
|---|---|---|
| Pneumonia infectionInfections and infestations | 1/64 | 0/64 |
| Event | IVIEW-1201 | Ofloxacin Eye Drops |
|---|---|---|
| Eye PainEye disorders | 11/64 | 0/64 |
| Age, Continuous(Years) | IVIEW-1201 | Ofloxacin Eye Drops | Total |
|---|---|---|---|
| Mean | 57.60 ± 14.58 | 56.06 ± 13.83 | 56.84 ± 14.18 |
| Sex: Female, Male(Participants) | IVIEW-1201 | Ofloxacin Eye Drops | Total |
|---|---|---|---|
| Female | 41 | 36 | 77 |
| Male | 24 | 28 | 52 |
| Race/Ethnicity, Customized(Participants) | IVIEW-1201 | Ofloxacin Eye Drops | Total |
|---|---|---|---|
| Ethnicity — Han | 61 | 62 | 123 |
| Ethnicity — Others | 4 | 2 | 6 |
| Height(cm) | IVIEW-1201 | Ofloxacin Eye Drops | Total |
|---|---|---|---|
| Mean | 163.43 ± 7.52 | 165.13 ± 8.10 | 164.27 ± 7.83 |
| Weight(kg) | IVIEW-1201 | Ofloxacin Eye Drops | Total |
|---|---|---|---|
| Mean | 64.69 ± 11.07 | 64.68 ± 11.10 | 64.68 ± 11.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2023 to primary completion in Nov 2023, 10 months.
Results were first posted in Jun 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IVIEW-1201
IVIEW Therapeutics Inc.